Oncolytics Biotech Inc., abbreviated as ONCY, is a pioneering biotechnology organization based in Calgary, Alberta, Canada. Established in 1998, the company has dedicated over two decades to the development of oncolytic virus therapies - a novel way of treating specific cancers.
The heart of the company's breakthrough endeavor lies in REOLYSIN, its proprietary formulation of the human Respiratory Enteric Orphan Virus (Reovirus), a naturally occurring non-enveloped, double stranded RNA virus that selectively targets oncogenic Ras cells. Oncogenic Ras provides a unique opportunity since it is present in numerous cancer types. The ability of this virus to kill cancer cells while sparing the healthy cells has enabled significant strides in treating a variety of malignancies.
Oncolytics' mission is not just to develop novel therapies but to contribute to an overall improved survival and quality of life for people with cancer around the world. Through time, the company has established a unique position in the oncology field with its inventive approach, and it continues to evolve with its partnerships and collaborations to drive the science of immuno-oncology forward.
Some of their collaborators include giants of the industry like Pfizer and Merck, with whom Oncolytics is involved in clinical trials to examine the potential of combining their immunotherapies to create a potent and comprehensive cancer-killing tool.
In 2020, the company expanded its business model to include commercial and partnership strategies with the addition of Matt Coffey as President and CEO. Under his leadership, Oncolytics Biotech Inc. hopes to push its innovative cancer treatment methodologies to the forefront of the global health industry.
ONCY, traded on the Toronto Stock Exchange and on the NASDAQ, maintains a significant presence in the market, reflecting the promising growth potential of its cutting-edge treatments. As the company expands its reach deeper into immuno-oncology and pave new ways, Oncolytics Biotech Inc. continues to offer unique value and substantial hope in the field of cancer therapeutics.
In a society where cancer remains one of the leading causes of death, the role of companies like Oncolytics Biotech Inc. is more important than ever. They are at the vanguard of scientific innovation and are working tirelessly to make cancer a thing of the past. With each passing day, Oncolytics’ unique approach helps reconstruct the future of oncology, marking significant strides in the fight against this devastating disease.